Siemens’ new name, 6/16
June 2016—On May 4 Siemens Healthcare unveiled its new name, Siemens Healthineers. According to a company statement, the name “embodies the company’s pioneering spirit and engineering expertise in the healthcare industry.”
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Autoimmune thyroid disease tests, 6/16
June 2016—Thermo Fisher Scientific received 510(k) clearance for two new EliA IgG tests for detecting anti-thyroglobulin and anti-thyroid peroxidase autoantibodies in serum or plasma. The CLIA-moderate laboratory tests are performed on the fully automated Phadia 250, 2500, and 5000 laboratory systems.
IVD antibodies for IHC, 5/16
May 2016—Bio SB is offering 50 new antibodies for in vitro diagnostic applications. This generation of antibodies offers higher affinity, sensitivity, and specificity when compared with the previous generation of mouse monoclonal and polyclonal antibodies traditionally used in diagnostic immunohistochemistry applications. “Our new RBT and EP clones of rabbit monoclonal antibodies are unique reagents for cancer research and diagnostics,” Alfonso Heras, DVM, PhD, president and CEO of Bio SB, said in a statement. Among them are BRAF V600E, B7/H3,
PCR system, assay receive medical device license, 5/16
May 2016—Luminex received medical device licenses from Health Canada’s Therapeutic Products Directorate, Medical Devices Bureau, for the Aries System and Aries HSV 1&2 Assay; both were FDA cleared in October 2015 and were subsequently launched in the U.S. market.
3-D in vivo confocal microscope, 5/16
May 2016—MR Solutions’ 3-D in vivo confocal microscope for use in preclinical research provides a magnification range of up to 1,000 times, allowing researchers to examine cellular details within a live small animal, eliminating the need for a surgical biopsy.
Microinjection-ready Cas9 accelerate RNP, 5/16
May 2016—Horizon Discovery Group introduced its microinjection-ready Cas9 Accelerate Ribonucleoprotein. Cas9 Accelerate RNP maximizes gene-editing efficiency by enabling CRISPR …
Sysmex signs distribution agreement with Medline, 5/16
May 2016—Sysmex America has signed a nonexclusive distributor agreement with Medline Industries, a manufacturer and distributor of health care supplies.
Genomic test to predict prostate cancer progression, 5/16
ay 2016—GenomeDx Biosciences launched Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis, and cancer-specific death at the time of biopsy in men with prostate cancer.
FDA-cleared Graves’ disease assay, 5/16
May 2016—Siemens Healthcare Immulite 2000/2000 XPi TSI assay for the diagnosis of Graves’ disease is FDA cleared. The assay detects the presence of thyroid-stimulating antibodies only, is fully automated, and produces results in 65 minutes.
Mouse T- and B-lymphocyte kits, 5/16
May 2016—BD mouse T-lymphocyte and B-lymphocyte kits, protocols, and software templates for the BD Accuri C6 flow cytometer aim to simplify the identification of mouse T and B lymphocytes, their subsets, and their activation markers. The kits include fluorescent antibodies, buffer systems, and controls needed for acquisition and analysis.